Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia-Reference-Cited by-同舟云学术

Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia

Published:2022-06-09 Issue:8 Volume:97 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Gambacorti‐Passerini Carlo¹²^ORCID,Nicolini Franck Emmanuel³^ORCID,Larson Richard A.⁴,Aroldi Andrea¹²,Fontana Diletta²^ORCID,Piazza Rocco¹²,le Coutre Philipp⁵,Antolini Laura²,Assouline Sarit⁶

Affiliation:

1. Hematology Division ASST Monza Monza Italy

2. University of Milano‐Bicocca Monza Italy

3. Hematology Department & INSERM U1052 Centre Léon Bérard Lyon France

4. University of Chicago Chicago Illinois USA

5. Department of Hematology, Oncology, and Tumor Immunology Charité ‐ Universitätsmedizin Berlin Berlin Germany

6. Jewish General Hospital McGill University Montreal Quebec Canada

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26618

Reference12 articles.

1. Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

2. Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

3. First-line treatment of 102 chronic myeloid leukemia patients with imatinib: A long-term single institution analysis

4. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

5. Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events;Blood Cancer Journal;2023-08-11

2. Tyrosine kinase inhibitors dosing for chronic phase chronic myeloid leukemia : The case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day);American Journal of Hematology;2022-09-05